Dr. Meena Singh on Treating Vitiligo and Alopecia Areata with the Aerolase Exci308 | AAD 2026
Dr. Meena Singh shares how she uses the Aerolase Exci308 to treat vitiligo and alopecia areata, including pediatric protocols and 308nm excimer mechanism.
Dermatologist Dr. Meena Singh of Skin & Hair Center in Kansas City uses the Aerolase Exci308 as a frontline treatment tool for vitiligo and alopecia areata — two autoimmune conditions where conventional therapies frequently fall short. In this AAD 2026 presentation, Dr. Singh explains the clinical mechanism behind 308nm excimer therapy and how she applies it across adult and pediatric patients in her practice.
"This Exci light-based therapy has been a miracle for us — especially for disease states where we don't have great other options." — Dr. Meena Singh, Skin & Hair Center, Kansas City
Why Vitiligo and Alopecia Areata Are Difficult to Treat
Both vitiligo and alopecia areata are autoimmune conditions driven by immune complexes attacking specific tissues — melanocytes in vitiligo, hair follicle bulbs in alopecia areata. While topical preparations offer limited benefit, systemic immunosuppression carries significant side effect risk, and corticosteroid injections are often poorly tolerated — particularly in pediatric patients. The therapeutic gap is real, and for many patients, options are inadequate.
How the Aerolase Exci308 Works
The Exci308 delivers targeted 308nm narrowband UV light directly to affected areas. At this wavelength, excimer therapy reduces local auto-inflammation, suppresses cytotoxic T-cell activity, and creates the conditions for repigmentation in vitiligo and follicular regeneration in alopecia areata — without systemic effects or meaningful downtime.
Clinical Protocols and Patient Selection
Dr. Singh uses the Exci308 for vitiligo patients with focal, non-widespread involvement and for alopecia areata patients with near-complete scalp hair loss. Standard protocol is twice-weekly treatments over 8–12 weeks, with the option to increase to three sessions per week if response warrants. Treatment time per area is typically seconds, making it well-suited for patients — including young children — who cannot tolerate more invasive approaches.
A Delegatable, Practice-Friendly Device
Because the Exci308 has a minimal side effect profile and straightforward treatment settings, Dr. Singh delegates all treatments to her medical assistants. Patients come in two to three times per week without crowding the physician schedule — a workflow advantage that makes the device viable at high volume even in a smaller independent practice.
Presented by Meena Singh, MD
Dr. Meena Singh is a board-certified dermatologist and founder of Skin & Hair Center in Kansas City. She specializes in autoimmune and inflammatory skin conditions, with a clinical focus on vitiligo and alopecia areata across both adult and pediatric populations. Dr. Singh incorporates the Aerolase Exci308 as a core treatment tool in her practice, using targeted 308nm excimer therapy as a first-line option for patients where conventional treatments are limited or poorly tolerated.
How 308nm Excimer Therapy Works Alongside Modern Autoimmune Treatments
Join dermatologist Sophia Reid, MD to explore how 308nm excimer therapy complements and accelerates modern autoimmune treatments for Vitiligo, Psoriasis, Atopic Dermatitis, and more — with real-world protocols, case studies, and combination therapy insights.
Profitability with Phototherapy: Targeted 308nm For Chronic Skin Diseases
Join Dr. Francisca Kartono as she reveals how Aerolase's Exci308 delivers real clinical results where other approaches fall short—with faster chair time per patient, streamlined protocols, and a practice-friendly economic model.
Innovations in Treating Vitiligo and Leukoderma
Cheryl Burgess, MD, takes center stage to address the pressing concerns of medical professionals seeking advancements in Vitiligo and Leukoderma treatment.